MetLife stock holds steady as Q2 2026 earnings beat supports outlook

MetLife Inc. (US59156R1086) has backed its current valuation with a solid set of numbers in the quarter ended June 30, 2026, as adjusted earnings rose double digits and recent analyst actions underlined confidence in the insurer's strategy.

Per a Korean-language earnings summary dated August 6, 2026, covering results for the quarter ended June 30, 2026, MetLife reported adjusted earnings per share of $2.43, up 20% from the prior-year period, and adjusted net income of $1.573 billion, up 15% year over year. The same report highlighted a return on equity of 17% for the quarter, at the upper end of the company's target range.

Q2 2026 earnings growth

According to a Q2 2026 results overview published on August 25, 2026, MetLife's adjusted earnings per share of $2.43 for the quarter ended June 30, 2026 exceeded the prior-year period and reflected both higher net investment income and disciplined expense management. In dollar terms, adjusted net income of $1.573 billion for the quarter was 15% higher than in the same period of 2025, underscoring a robust profit trajectory.

The same summary indicated that MetLife delivered a 17% adjusted return on equity in Q2 2026, compared with a lower level in the prior-year quarter, placing profitability at the top end of the company's target band and signaling efficient use of capital. On a GAAP basis, net income for the quarter was $705 million, up 1% year over year, with GAAP earnings per share of $1.09, up 6% from the comparable quarter a year earlier.

Revenue and earnings mix

The Q2 2026 report also cited total revenue of $19.154 billion for the quarter ended June 30, 2026, reflecting a diversified mix of premiums, fees, and investment income. Compared with the prior-year period, this revenue base supported higher adjusted earnings, indicating that MetLife was able to expand profitability faster than topline growth.

From an investor perspective, the combination of a 20% increase in adjusted earnings per share to $2.43 and a 15% rise in adjusted net income to $1.573 billion in Q2 2026 suggests that operating leverage and capital management remain key drivers. The 17% adjusted return on equity for the quarter compares favorably with many global life insurers that often report mid-teens ROE levels, offering a competitive profitability profile.

Analyst views and price targets

An analyst update dated August 24, 2026 reported that a major investment bank maintained an overweight stance on MetLife shares while raising its price target from $103 to $111, a 7.77% upward revision. This higher target indicates that the analyst sees further upside potential relative to the prior valuation framework, even after the stock's recent gains.

The same update referenced a fair-value estimate of $92.96 for MetLife shares versus a prevailing share price of $95.63, implying the stock was trading 2.9% above that valuation benchmark as of the note's publication. At that level, MetLife shares were assessed as modestly overvalued, suggesting that investors were willing to pay a premium in light of the company's 17% adjusted return on equity in Q2 2026 and its double-digit earnings growth.

Institutional interest and consensus

A portfolio disclosure post dated August 25, 2026 highlighted that a large financial institution initiated a new position in MetLife worth $14.18 million, signaling continued institutional interest in the insurer. The same item stated that the stock carried an average rating of buy and a consensus target price of $102.21, indicating that, on average, covering analysts still see additional upside from levels cited in recent valuation discussions.

For investors, the combination of a raised individual price target to $111, a consensus target of $102.21, and a current price reference of $95.63 relative to an indicated value of $92.96 suggests a nuanced valuation picture. MetLife shares are not deeply discounted on some fair-value models, but consistent earnings growth and a 17% adjusted return on equity in Q2 2026 provide a fundamental backdrop that many analysts view favorably.

Dividend and income profile

A dividend-focused stock overview updated on August 24, 2026 showed MetLife listed on the New York Stock Exchange under the ticker MET with a real-time reference price of $74.90 as of that source's timestamp. While price references vary across portals due to different update times and methodologies, the listing underscores MetLife's status as a large-cap U.S. insurer that has historically paid regular dividends.

Income-oriented investors often evaluate MetLife in the context of its dividend history and yield, alongside its earnings power. With adjusted earnings per share of $2.43 in Q2 2026 alone and a 17% adjusted return on equity for the quarter, the company has demonstrated capacity to support capital returns while investing in growth and maintaining regulatory capital buffers.

MetLife insurance offerings

Beyond headline earnings and stock metrics, MetLife generates its results from a broad portfolio of insurance and protection products, including life, dental, and other benefits solutions for both individuals and institutional clients. Its ability to deliver adjusted net income of $1.573 billion in Q2 2026 and a 17% adjusted return on equity for that period reflects the scale and diversity of these offerings.

In the U.S. and international markets, the insurer's product suite supports steady premium and fee income, which contributed to total revenue of $19.154 billion in the quarter ended June 30, 2026. For shareholders, the stability of this revenue base underpins the quarter's 20% year-over-year growth in adjusted earnings per share to $2.43 and supports the longer-term case for MetLife stock as a key player in the global insurance sector.

MetLife stock valuation snapshot

MetLife shares trade on the New York Stock Exchange under the ticker MET, providing U.S. retail investors direct exposure to one of the world's largest life insurers. As referenced in a valuation-oriented note dated August 24, 2026, MetLife stock was cited at $95.63 versus a calculated value of $92.96, indicating a 2.9% premium to that metric.

While different data sources provided reference prices such as $95.63 and $74.90 as of their respective August 2026 update times, the overall message for investors is that MetLife stock is supported by strong Q2 2026 fundamentals, including adjusted earnings per share of $2.43, adjusted net income of $1.573 billion, and a 17% adjusted return on equity for the quarter.

Read more

Q2 2026 MetLife earnings overview

Analyst price target update for MetLife

Institutional investment disclosure for MetLife

MetLife product focus

MetLife's core franchise rests on providing life insurance, annuities, and employee benefits such as group life and dental coverage, which together generate the premium and fee income reflected in its $19.154 billion of total revenue for the quarter ended June 30, 2026. These protection and benefits solutions help drive consistent cash flows that supported the company's 20% year-over-year increase in adjusted earnings per share to $2.43 in Q2 2026.

MetLife stock and investor takeaway

As of late August 2026, MetLife stock reflects a balance between solid Q2 2026 fundamentals and valuations that some models classify as modestly above fair value, with a cited price of $95.63 compared with an indicated value of $92.96 and a consensus target of $102.21. For investors, the key metrics remain the quarter's 17% adjusted return on equity, 20% growth in adjusted earnings per share to $2.43, and 15% growth in adjusted net income to $1.573 billion, which collectively frame the risk-reward profile of MetLife shares.

Fact box

Company: MetLife Inc.

ISIN: US59156R1086

Ticker: MET

Exchange: New York Stock Exchange

Sector / Industry: Financials / Insurance

Index membership: S&P 500